Hyperion Therapeutics Announces Second Quarter 2013 Financial Results
Teleconference and Webcast
SOUTH SAN FRANCISCO, Calif., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Hyperion
Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will host a
teleconference and webcast with management to provide a general business
overview, as well as to discuss its second quarter 2013 financial results on
Wednesday, August 14, 2013 at 4:30 p.m. EDT (1:30 p.m. PDT.) Financial results
for the quarter ended June 30, 2013 will be released after market close on
August 14, 2013.
To access the live conference call, dial 877-847-7188 U.S. or 408-427-3787
International and use the conference ID# 21769835. Individuals may access the
live audio webcast at http://investors.hyperiontx.com/events.cfm. A replay of
the webcast will be available on the Company's website for 30 days following
the live event.
About Hyperion Therapeutics
Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan
diseases and hepatology. The company's first commercial product, Ravicti®
(glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is
currently being marketed in the United States. The company also owns and
markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder worldwide. For
more information, please visit www.hyperiontx.com.
CONTACT: Sylvia Wheeler, Investor Relations
Press spacebar to pause and continue. Press esc to stop.